NCT05755217Completed
Renal Ultrasound Response After Chocolate Consumption
Study of the Renal Physiological Response After Chocolate Consumption
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
The consumption of dark chocolate (DC) has antihypertensive (3) and anti-inflammatory effects. Some studies also suggest that dark chocolate may also have cardiovascular benefits, but its physiological effects on the kidneys have not been studied in detail. In this randomized, single-blinded, controlled, monocentric cross-over study we will investigate whether the ingestion of a single dose of dark chocolate (g/kg, max 70g) leads to alterations in renal perfusion and blood pressure two hours after its consumption in healthy volunteers and patients suffering from chronic kidney disease. The Doppler-ultrasound assessed renal resistive index (RRI) will be used at baseline and two hours after chocolate consumption as an indirect measure of renal perfusion. Blood pressure and heart rate will be measured continuously using the Finapres® NOVA (Finapres Medical Systems, Enschede, The Netherlands) throughout the Doppler ultrasound examination. In order to compare the effects of dark chocolate with those obtained with white chocolate, participants will undergo a similar sequence of exames after the consumption of white chocolate.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 33 (actual)
- First submitted
- 23 Feb 2023
- Start date
- 22 Feb 2023
- Primary completion date
- 17 Sept 2025
- Lead sponsor
- Gregoire Wuerzner; MD
- Diseases
- Chronic kidney disease
- NCT number
- NCT05755217
What you commit to
- Study type: Interventional
- Participants enrolled: 33
- From 22 Feb 2023 to the primary completion date, 17 Sept 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- healthy volunteers taking antihypertensive medication
Other illness
- Diabetes,
- any severe digestive issue and liver disease,
- history of kidney stones,
- inability to follow the procedures of the study, e.g. due to language problems, dementia, etc.
Lab values
- CKD patients with an eGFR\<30ml/min/1.73m2
Other
- Lactose or cocoa intolerance,
- pregnant women
- healthy volunteers having a known kidney malformation or abnormality
- healthy volunteers with albuminuria and/or hematuria in the urine sample.
- CKD patients with measured kalemia of \> 5.5mmol/l in the last three months.
Who the study is looking for
- Age ≥ 18 years old
- ability to understand the study protocol and to sign an informed consent.
- Age ≥18 years old,
- CKD stage 1-3,
- ability to understand the study protocol and to sign an informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Lausanne (CHUV) Coordinator of this site? Confirm its status | Lausanne | Switzerland | Unknown status |
| Department of Nephrology, Centre Hospitalier Universitaire Vaudois Coordinator of this site? Confirm its status | Lausanne | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.